

Natura Myeku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5460902/publications.pdf>

Version: 2024-02-01

8
papers

511
citations

1478505

6
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

1045
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. <i>Nature Medicine</i> , 2016, 22, 46-53.	30.7	352
2	Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases. <i>Trends in Molecular Medicine</i> , 2018, 24, 18-29.	6.7	39
3	Assessment of Proteasome Impairment and Accumulation/Aggregation of Ubiquitinated Proteins in Neuronal Cultures. <i>Methods in Molecular Biology</i> , 2011, 793, 273-296.	0.9	38
4	cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons. <i>Neuroscience Letters</i> , 2012, 527, 126-131.	2.1	34
5	Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline. <i>Translational Research</i> , 2018, 193, 31-41.	5.0	27
6	PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	18
7	Investigating changes in the proteostasis capabilities of iPSC neurons during development and in FTD using iPSC neurons with <i>MAPT</i> mutations. <i>Alzheimer's and Dementia</i> , 2021, 17, e058308.	0.8	1
8	P3154: STOPPING TRANSYNAPTIC PROPAGATION OF TAU BY RECEPTOR-MEDIATED CLEARANCE OF POSTSYNAPTIC TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P1127.	0.8	0